Articles related to RESEARCH & CLINICAL TRIALS

I-SPY2 Reveals High pCR Rates in Difficult-to-Treat Breast Cancers

The I-SPY2 trial demonstrates that novel treatment approaches can yield high pathologic complete response rates in rare histologic subtypes of high-risk breast cancer, potentially improving outcomes for these challenging cases.

Medical Oncology August 26th 2024

Tags: BREAST CANCER IMMUNOTHERAPY NEOADJUVANT TREATMENT PRECISION MEDICINE RESEARCH & CLINICAL TRIALS

Rare Disease Advisor

Gene Therapy Shows Long-Term Efficacy in Hemophilia A

Valoctocogene roxaparvovec gene therapy demonstrates long-term efficacy in reducing bleeding episodes and factor VIII use in patients with severe hemophilia A, potentially changing the treatment landscape for this condition.

Hematology August 26th 2024

Tags: BLEEDING/BLOOD DISORDERS GENE THERAPY HEMOPHILIA RESEARCH & CLINICAL TRIALS

Cleveland Clinic Journal of Medicine (CCJM)

Stellate Ganglion Block as a Treatment for Vasomotor Symptoms: Clinical Application

Stellate ganglion block reduces vasomotor symptom frequency by 4-90% in clinical trials, offering a potential non-hormonal option for women with severe symptoms refractory to conservative care.

Obstetrics & Gynecology August 26th 2024

Tags: HEALTHCARE DELIVERY LIFESTYLE & WELLNESS PATIENT CARE RESEARCH & CLINICAL TRIALS TREATMENTS & PROCEDURES WOMEN'S HEALTH

<< 1 2 … 25 26

Trending Topics:

Articles related to RESEARCH & CLINICAL TRIALS

I-SPY2 Reveals High pCR Rates in Difficult-to-Treat Breast Cancers

Gene Therapy Shows Long-Term Efficacy in Hemophilia A

Stellate Ganglion Block as a Treatment for Vasomotor Symptoms: Clinical Application

Topics

Sources

The Healthcare Communications Network is owned and operated by IQVIA Inc. Click below to leave this site and continue to IQVIA’s Privacy Choices form

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form